Cisatracurium Besylate Injection USP
Subpotent product:out of specification assay results observed during long term stability testing.
Yes — there is an active recall. 3 ongoing FDA recalls mention Cisatracurium (6 total). Check the affected lots below.
Most common reason: Wrong potency / content (3 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Cisatracurium. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Subpotent product:out of specification assay results observed during long term stability testing.
Subpotent product:out of specification assay results observed during long term stability testing.
Subpotent product:out of specification assay results observed during long term stability testing.
Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium
Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Preservative free on the individual carton label. The vial label and outer carton label contain the correct statement of 0.9% benzyl alcohol added as a preservative.
Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.